Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Climbed Today

By Joe Tenebruso - Updated Mar 15, 2021 at 5:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech is testing a "next-generation" coronavirus vaccine.

What happened

Shares of Moderna (MRNA -0.92%) rose 4.9% on Monday, after the biotechnology company said it began a study of an experimental COVID-19 vaccine with less restrictive storage requirements.

So what 

Moderna dosed the first participants in its phase 1 trial of mRNA-1283, the biotech's refrigerator-stable COVID-19 vaccine candidate. Should it prove both safe and effective, the new vaccine would be easier to transfer, store, and administer, according to CEO Stephane Bancel. That could make it particularly compelling for distribution in markets with less advanced healthcare infrastructure.

A person is pointing to a rising digital stock chart.

Investors bid up Moderna's stock price on Monday. Image source: Getty Images.

The phase 1 study is designed to evaluate the safety and immunogenicity of mRNA-1283. Moderna will test several different dose levels of the drug. The results will be compared to those of mRNA-1273, Moderna's authorized COVID-19 vaccine.

Moderna also plans to conduct future studies to evaluate mRNA-1283 as a potential booster dose for previously vaccinated people.

Now what 

Moderna's mRNA-1273 has demonstrated remarkable efficacy against COVID-19 in clinical trials. The vaccine has also been shown to be safe and generally well tolerated. However, when stored for periods of more than 30 days, the drug must be stored frozen between -25 and -15 degrees Celsius (-13 to 5 degrees Fahrenheit). These storage requirements can prove challenging for many developing countries.

A refrigerator-stable COVID-19 vaccine would be easier to distribute in areas where freezers are harder to come by. Such a drug would help to expand Moderna's addressable market, as well as its long-term profit potential.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$130.85 (-0.92%) $-1.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.